![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TMEM86B |
Gene summary for TMEM86B |
![]() |
Gene information | Species | Human | Gene symbol | TMEM86B | Gene ID | 255043 |
Gene name | transmembrane protein 86B | |
Gene Alias | TMEM86B | |
Cytomap | 19q13.42 | |
Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q8N661 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
255043 | TMEM86B | S43 | Human | Liver | Cirrhotic | 8.63e-04 | -1.13e-01 | -0.0187 |
255043 | TMEM86B | HCC1_Meng | Human | Liver | HCC | 1.46e-38 | -3.21e-02 | 0.0246 |
255043 | TMEM86B | cirrhotic1 | Human | Liver | Cirrhotic | 2.83e-04 | 2.17e-01 | 0.0202 |
255043 | TMEM86B | HCC2 | Human | Liver | HCC | 3.41e-03 | 1.81e+00 | 0.5341 |
255043 | TMEM86B | S014 | Human | Liver | HCC | 3.55e-21 | 1.18e+00 | 0.2254 |
255043 | TMEM86B | S015 | Human | Liver | HCC | 7.23e-21 | 1.58e+00 | 0.2375 |
255043 | TMEM86B | S016 | Human | Liver | HCC | 2.34e-31 | 1.42e+00 | 0.2243 |
255043 | TMEM86B | S028 | Human | Liver | HCC | 3.59e-02 | 1.07e-02 | 0.2503 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | ![]() |
Oral cavity | LP | ![]() |
Oral cavity | EOLP | ![]() |
Oral cavity | NEOLP | ![]() |
Esophagus | HGIN | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
GO:00066504 | Liver | HCC | glycerophospholipid metabolic process | 168/7958 | 306/18723 | 7.27e-06 | 8.62e-05 | 168 |
GO:0036151 | Liver | HCC | phosphatidylcholine acyl-chain remodeling | 11/7958 | 14/18723 | 6.81e-03 | 2.73e-02 | 11 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TMEM86B | SNV | Missense_Mutation | c.478N>T | p.Ala160Ser | p.A160S | Q8N661 | protein_coding | tolerated(0.76) | benign(0.185) | TCGA-EI-6507-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
TMEM86B | SNV | Missense_Mutation | rs755163968 | c.145N>A | p.Ala49Thr | p.A49T | Q8N661 | protein_coding | deleterious(0.02) | benign(0.06) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
TMEM86B | SNV | Missense_Mutation | novel | c.265N>A | p.Ala89Thr | p.A89T | Q8N661 | protein_coding | tolerated(0.09) | benign(0.155) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMEM86B | SNV | Missense_Mutation | rs191683509 | c.169G>A | p.Val57Ile | p.V57I | Q8N661 | protein_coding | tolerated(0.92) | benign(0.018) | TCGA-AP-A1DH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMEM86B | SNV | Missense_Mutation | novel | c.656G>T | p.Arg219Met | p.R219M | Q8N661 | protein_coding | deleterious(0.02) | benign(0.359) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMEM86B | SNV | Missense_Mutation | novel | c.241N>A | p.Leu81Ile | p.L81I | Q8N661 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
TMEM86B | SNV | Missense_Mutation | novel | c.62T>C | p.Val21Ala | p.V21A | Q8N661 | protein_coding | tolerated(0.37) | benign(0.011) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TMEM86B | SNV | Missense_Mutation | rs774125408 | c.100N>A | p.Val34Met | p.V34M | Q8N661 | protein_coding | deleterious(0) | benign(0.421) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
TMEM86B | SNV | Missense_Mutation | rs751805183 | c.490N>T | p.Arg164Cys | p.R164C | Q8N661 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-KK-A59V-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Unknown | Unknown | SD |
TMEM86B | SNV | Missense_Mutation | c.593N>T | p.Ala198Val | p.A198V | Q8N661 | protein_coding | deleterious(0.01) | possibly_damaging(0.703) | TCGA-CD-A4MG-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |